摘要
目的:观察人脑胶质瘤组织中肿瘤干细胞标记物CD133与表皮生长因子受体Ⅲ型突变体(epidermal growth factorreceptor variantⅢ,EGFRvⅢ)的共表达情况及其临床意义。方法:取河南省人民医院自2011年1月至2011年6月手术切除的脑胶质瘤组织40例,其中Ⅱ级17例、Ⅲ级12例、Ⅳ级11例。流式细胞术检测不同级别脑胶质瘤中CD133+、EGFRvⅢ+和CD133+/EGFRvⅢ+细胞所占的比例,分析其临床意义。结果:CD133、EGFRvⅢ在人脑胶质瘤组织中的表达率及其阳性表达细胞比例均随肿瘤级别逐步升高(均P﹤0.05)。不同级别脑胶质瘤中均发现CD133和EGFRvⅢ共表达细胞,CD133+/EG-FRvⅢ+细胞共表达率在(4.75±1.26)%～(18.26±3.45)%之间,Ⅲ、Ⅳ级胶质瘤中CD133+/EGFRvⅢ+细胞的共表达率高于Ⅱ级(P﹤0.05)。CD133+/EGFRvⅢ+细胞比CD133+细胞、EGFRvⅢ+细胞对脑胶质瘤患者的生存期影响更大,共表达细胞患者的中位生存时间明显缩短。结论:人脑胶质瘤组织中存在CD133+/EGFRvⅢ+共表达细胞,其与胶质瘤的恶性程度及患者生存时间有关,本研究为脑胶质瘤的靶向治疗提供了潜在新的靶点。
Objective： To observe the co-expressions of human glioma tumor stem cell marker （CD133） and epidermal growth factor receptor variant Ⅲ（EGFRvm） in the glioma tissues and their clinical significance. Methods： Forty glioma samples （17 with grade Ⅱ, 12 with grade Ⅲ, Ⅱ with grade IV） were obtained from patients with glioma （who had been diagnosed in the Peo- ple＇s Hospital, Zhengzhou University, from Jan. 2011 to Jun. 2011 ） receiving surgery. The percentages of CD133 ＋, EGFRv m＋ and CD133 ＋/EGFRvlII ＋ cells in the glioma tissues in different grades were analyzed by flow cytometry and the clinical fea- tures were compared. Results： The expression of CD133 and EGFRvⅢ in human glioma increased gradually with the pathologic grade of glioma tissue. The double positive CD133 ＋/EGFRvⅢ＋ cells were found in the glioma tissues of different grades. The percentage of CD133 ＋/EGFRvⅢ＋ cells was between （4.75 ± 1.26）% to （18.26 ±3.45）% in different grades of gliomas, with the percentages of CD133 ＋/EGFRvⅢ＋ cells in grade m and IV being higher significantly than that in grade 11 （P 〈 0.05）. CD133 ＋/EGFRvⅢ ＋ cells exerted much more influence than did cells expressing CD133 ＋ or EGFRvⅢ＋ on survival time of the gliomas patients, and the median survival time of the patients with double positive CD133 ＋/EGFRvⅢ＋ was shorter. Conclu- sion： The co-expressions of CD133 and EGFRvlII exist in human gliomas, which are related with the degree of malignant glioma and the survival rate. Our study provides a new potential target for the treatment of glioma.
出处
《中国肿瘤生物治疗杂志》
CAS
CSCD
北大核心
2012年第6期628-631,共4页
Chinese Journal of Cancer Biotherapy
基金
国家自然科学基金资助项目(No.81172415)~~
